Kintor Pharmaceutical Ltd (hkse:09939) Share Price

Company Profile

Business description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.
Contact
No. 20 Songbei Road
Suzhou Industrial Park
Jiangsu
Suzhou215123
CHN
T: +86 51262639909
https://www.kintor.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
136

Recommended

These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 27 January 2026

Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.

Sarah Hansen | 26 January 2026

Higher diesel prices and foreign exchange hit unit cash costs.

Jon Mills, CFA | 26 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,268.50	10.00	0.11%
CAC 40	8,152.82	21.67	0.27%
DAX 40	24,894.44	38.64	-0.15%
Dow JONES (US)	48,967.47	444.93	-0.90%
FTSE 100	10,207.80	58.95	0.58%
HKSE	27,126.95	361.43	1.35%
NASDAQ	23,841.20	239.85	1.02%
Nikkei 225	53,333.54	448.29	0.85%
NZX 50 Index	13,510.88	50.14	0.37%
S&P 500	6,983.31	33.08	0.48%
S&P/ASX 200	8,941.60	14.90	0.17%
SSE Composite Index	4,139.90	7.30	0.18%